$39.55
-0.47 (-1.17%)
Open$40.08
Previous Close$40.02
Day High$40.29
Day Low$39.05
52W High$49.32
52W Low$28.95
Volume—
Avg Volume454.6K
Market Cap2.04B
P/E Ratio84.14
EPS$0.42
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+10.2% upside
Current
$39.55
$39.55
Target
$43.60
$43.60
$27.22
$43.60 avg
$49.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 281.59M | 236.85M | 156.14M |
| Net Income | 16.83M | 12.74M | 35.53M |
| Profit Margin | 6.0% | 5.7% | 22.8% |
| EBITDA | 23.02M | 18.40M | 44.60M |
| Free Cash Flow | — | — | 32.60M |
| Rev Growth | +18.9% | +18.9% | +24.7% |
| Debt/Equity | 0.01 | 0.01 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |